Recombinant Full Length Human S100A9, None tagged

• Cat.No.: S100A9-3879H
• Product Overview: Recombinant Human S100A9 (NP_002956.1) native form (Met 1-Pro 114), fused with no tag, was produced in E. coli.

Specification

• Source: E. coli
• Species: Human
• Form: Lyophilized from sterile PBS, pH 7.4
• Molecular Mass: The recombinant human S100A9 consisting of 114 amino acids and migrates with an apparent molecular mass of 26 & 13 kDa corresponding to dimeric and monomeric form as estimated in SDS-PAGE under Non-reduced condition.
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Stability: Samples are stable for up to twelve months from date of receipt at -70oC.
• Storage: Store it under sterile conditions at -20oC~-70oC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution. Centrifuge the vial at 4℃ before opening to recover the entire contents.
• Tag: Non
• Protein Length: 1-114 a.a.

Gene Information

• Gene Name: S100A9 S100 calcium binding protein A9 [ Homo sapiens ]
• Official Symbol: S100A9
• Gene ID: 6280
• mRNA Refseq: NM_002965
• Protein Refseq: NP_002956
• MIM: 123886
• UniProt ID: P06702

Reviews

08/17/2021

This includes complementary reagents, protocols, and access to an extensive knowledge base, all aimed at streamlining the trial process and maximizing the chances of achieving meaningful results.

06/20/2016

By choosing the S100A9 protein and partnering with the manufacturer, researchers can confidently conduct their trials, achieve reliable results, and contribute to groundbreaking discoveries.

04/04/2016

Collaborating with the manufacturer opens up possibilities for potential collaboration and exchange of information with a wider scientific community, allowing researchers to stay at the forefront of advancements in their respective fields.

Q&As

How is S100A9 protein measured in clinical settings?

S100A9 levels can be measured using various laboratory techniques, such as ELISA (enzyme-linked immunosorbent assay).

Are there any therapies or drugs targeting S100A9 in clinical development?

Some research is exploring the development of drugs that target S100A9 to modulate inflammation, but clinical applications are still in the experimental phase.

Can S100A9 levels be used as a biomarker for specific diseases?

Yes, elevated S100A9 levels have been associated with conditions like rheumatoid arthritis and inflammatory bowel disease, making it a potential biomarker.

Can S100A9 be used to predict disease outcomes?

Elevated S100A9 levels have been linked to poorer outcomes in certain diseases, making it a potential predictor of disease severity.

Are there any genetic factors that influence S100A9 levels?

Genetic variations can influence S100A9 expression, and these variations may impact an individual's susceptibility to certain diseases.